F-18 Sodium Fluoride Bone PET/CT: Physics & QC

Introduction

F-18 sodium fluoride (NaF) is a bone-seeking positron-emitting tracer that images active bone metabolism with markedly higher spatial resolution and target-to-background ratio than conventional Tc-99m bone scintigraphy. Paired with CT for anatomic localization and attenuation correction, NaF PET/CT is a high-performance skeletal imaging tool — quantitative, fast, and increasingly used for detecting and monitoring osteoblastic disease such as bone metastases.¹⁵

For the medical physicist and nuclear medicine team, NaF PET/CT is quantitative PET applied to bone. That means the same disciplines that govern any SUV-based PET program — dose-calibrator accuracy, scanner cross-calibration, NEMA NU 2 performance, attenuation correction, and reconstruction consistency — determine whether NaF numbers are trustworthy.⁶⁷ It also means the tracer's own physics, kinetics, and dosimetry deserve explicit attention, because they differ substantially from FDG.

This guide covers the tracer physics and bone kinetics, SUV quantification and the attenuation-correction pitfalls that most affect NaF, patient dosimetry using current ICRP coefficients, and the QC and cross-calibration a defensible program needs. DRPS supports NaF PET/CT programs through its PET/CT and nuclear medicine physics and accreditation support services.

Topic Explanation

What is F-18 NaF and how does it localize in bone?

F-18 NaF localizes in bone by chemisorption: fluoride ions exchange with hydroxyl groups in bone hydroxyapatite to form fluorapatite, preferentially at sites of high bone turnover and regional blood flow. Uptake therefore reflects osteoblastic activity — the same physiologic signal as a Tc-99m MDP bone scan, but delivered by a positron emitter with superior imaging characteristics.¹⁵

NaF has favorable pharmacokinetics for imaging: rapid single-pass extraction by bone, fast clearance from blood and soft tissue, and renal excretion, which together produce a high bone-to-background ratio within roughly an hour of injection.¹ The tracer is a small ion with essentially no metabolism, so its behavior is governed by blood flow and bone-surface availability rather than complex biochemistry — one reason NaF kinetics are amenable to quantitative modeling.

For the planar/SPECT counterpart this study largely improves upon, see our guide to Tc-99m MDP bone scintigraphy.

Physical properties of F-18

F-18 is produced on a medical cyclotron (see cyclotron production of fluorine-18) and decays with a physical half-life of 109.77 minutes, primarily by positron emission (β⁺ branching ~96.7%), with a relatively low positron endpoint energy that supports good PET spatial resolution.¹ The 511 keV annihilation photons are imaged by the PET scanner exactly as for any positron emitter, so NaF slots directly into an existing PET/CT workflow.

Key Technical Principles

Decay correction and imaging window

All quantitative PET rests on accurate decay correction. For an initial activity $A_{0}$ and elapsed time $t$ , the remaining activity is:

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{T _{1/2}}

With $T_{1/2} = 109.77$ min, the decay constant is $λ = ln 2/109.77 \approx 6.31 \times 1 0^{- 3} min^{- 1}$ . For a typical 60-minute uptake period, the surviving fraction of injected activity is:

\frac{A ( 60 )}{A _{0}} = e^{- (6.31 \times 1 0^{- 3}) (60)} \approx e^{- 0.379} \approx 0.685

so roughly 68% of the administered F-18 remains at the start of imaging. This short half-life is why injected-activity time stamps and clock synchronization are not clerical details but direct inputs to SUV accuracy.⁶

SUV quantification

The standardized uptake value normalizes tissue activity concentration to injected activity and body mass:

SUV = \frac{C _{t} ( Bq/mL )}{A _{inj} ( Bq ) / BW ( g )}

assuming a tissue density of 1 g/mL. As a worked example, a vertebral lesion with a decay-corrected activity concentration of 20 kBq/mL in a patient injected with 300 MBq at a body weight of 80 kg gives:

SUV = \frac{20 , 000}{300 \times 1 0 ^{6} /80 , 000} = \frac{20 , 000}{3 , 750} \approx 5.3

For NaF, SUV is a practical semi-quantitative index of osteoblastic activity and has been used to assess treatment response in metastatic disease.³ More rigorous kinetic analysis (for example, dynamic acquisition with Patlak modeling to estimate the plasma-to-bone transport rate $K_{i}$ ) is used in research and quantitative-response settings, but static SUV dominates routine clinical practice. For a fuller treatment of SUV mechanics and pitfalls, see PET SUV quantification.

Attenuation correction: why bone is special for NaF

Accurate attenuation correction (AC) is essential for correct SUV, and NaF exposes AC weaknesses more than most tracers because its signal is the bone — the most attenuating tissue in the body. On PET/CT this is well handled: the CT provides a direct, high-resolution attenuation map. The problem appears on PET/MR, where standard MR-based AC (Dixon segmentation into air, lung, fat, and soft tissue) ignores cortical bone. Published work shows that neglecting bone attenuation underestimates SUV in pelvic and spinal lesions by roughly 8%, with individual vertebral lesions underestimated by more.⁵⁶ Hybrid PET- and MR-driven AC methods that reintroduce a bone class substantially reduce this bias.⁶

The practical message: NaF quantification is most robust on PET/CT, and any NaF program running on PET/MR must understand and correct for the bone-AC problem. For the general principles, see PET/CT attenuation correction.

Reconstruction and TOF effects

Time-of-flight (TOF) reconstruction improves data statistics and modestly increases measured SUV in small osseous structures relative to non-TOF reconstruction; one study reported an average SUVmean increase on the order of ~2.5% in metastatic lesions with TOF, larger for smaller lesions.⁷ The effect is genuine but small, and the key QC lesson is consistency: TOF-versus-non-TOF and other reconstruction choices must be held fixed when comparing serial NaF studies or pooling across sites, or apparent SUV changes may reflect reconstruction rather than biology.⁷

NaF PET/CT versus Tc-99m MDP bone scintigraphy

Property	F-18 NaF PET/CT	Tc-99m MDP bone scintigraphy
Emission imaged	511 keV annihilation photons (β⁺)	140 keV gamma (single photon)
Physical half-life	109.77 min	6.0 h
Uptake / imaging delay	~30–90 min (commonly 45–60)	~2–4 h
Spatial resolution & target-to-background	Higher	Lower
Localization	Integrated CT (SPECT/CT for planar counterpart)	Planar ± SPECT/CT
Quantification	Quantitative SUV	Semi-quantitative at best
Adult administered activity	~185–370 MBq (5–10 mCi)¹	~740–1110 MBq (20–30 mCi)

The higher resolution, quantitation, and short uptake time explain NaF's growing role; the trade-off is PET/CT scanner time and cost.¹⁵

Clinical Impact

NaF PET/CT's main clinical value is high-sensitivity, quantitative detection and monitoring of skeletal disease, especially osteoblastic metastases from prostate and breast cancer. Its resolution and target-to-background advantages improve detection of small or early lesions, and the integrated CT improves specificity by characterizing the anatomic correlate (blastic, lytic, degenerative).¹⁵ Quantitative NaF metrics have shown promise as imaging biomarkers of treatment response; for example, quantitative total-bone-imaging measures of functional tumor burden on serial NaF PET/CT have correlated with progression-free survival in metastatic castration-resistant prostate cancer.³

Beyond oncologic staging, NaF's sensitivity to bone turnover supports a range of benign applications where regional osteoblastic activity is the signal of interest — back pain localization, suspected osteomyelitis and orthopedic hardware complications, metabolic bone disease, and stress or occult fractures. In these settings the combination of quantitative uptake and precise CT localization helps separate active from inactive or degenerative findings, which is often the clinical question. The tracer's short uptake time and whole-body coverage also make it efficient for surveying the entire skeleton in a single session.¹

From a physics standpoint, the clinical payoff depends entirely on quantitative integrity. If the dose calibrator is off, the scanner cross-calibration has drifted, or reconstruction settings changed between baseline and follow-up, a "response" or "progression" signal can be an artifact. NaF also delivers a relatively high count rate to the scanner because of its favorable bone uptake and clearance, so count-rate performance and the scanner's noise-equivalent count-rate curve — characterized under NEMA NU 2 — are worth understanding when pushing toward lower administered activity or faster acquisitions. That is why NaF response assessment leans so heavily on the daily QC and cross-calibration program described below and in our PET/CT daily QC and calibration guide.

Practical Optimization Tips

1. Anchor SUV to a verified cross-calibration chain

SUV is only as good as the weakest link among the dose calibrator, the scanner, and the clock. Maintain dose-calibrator accuracy and constancy, perform periodic scanner-to-dose-calibrator cross-calibration, and synchronize all clocks used for injection and acquisition time stamps. A cross-calibration error propagates directly and linearly into every SUV.⁶

2. Standardize the uptake time

Because NaF uptake and background clearance evolve over the first hour, hold the uptake interval consistent (for example, target 60 minutes and record the actual value). Variable uptake times introduce SUV variability unrelated to disease.¹

3. Lock reconstruction settings

Fix the reconstruction algorithm, iterations/subsets, filter, matrix, and TOF setting for a given clinical task, and document them. Change them only deliberately, and re-baseline serial patients if you do.⁷

4. Get attenuation correction right for your platform

On PET/CT, verify CT-based AC and watch for truncation and metal artifacts near dense bone. On PET/MR, use a bone-aware AC method and understand the residual SUV bias in the spine and pelvis.⁵⁶

5. Reduce bladder dose with hydration and voiding

The urinary bladder wall is the dose-limiting organ for NaF. Encourage hydration and frequent voiding, particularly after imaging, to clear excreted tracer and lower bladder dose.²⁴

6. Characterize the scanner with NEMA NU 2

Acceptance and periodic performance testing under NEMA NU 2 (spatial resolution, sensitivity, noise-equivalent count rate, scatter fraction, image quality, and SUV recovery) gives the objective baseline against which quantitative drift is detected. See PET/CT NEMA NU-2 performance testing.⁷

Common pitfalls

Treating NaF like FDG dosimetry. The dose coefficient and critical organ differ; use NaF-specific values.²⁴
Ignoring bone AC on PET/MR. Expect and correct the ~8% spinal/pelvic SUV underestimate.⁵⁶
Changing reconstruction mid-series. Apparent SUV change may be reconstruction, not biology.⁷
Loose time keeping. With a ~110-minute half-life, clock errors corrupt SUV.⁶

Regulatory Considerations

F-18 NaF is byproduct material used in medical imaging, so its possession and use fall under NRC or Agreement State medical-use regulation, while the clinical performance of the study is guided by professional standards.

10 CFR Part 35 (Medical Use of Byproduct Material) governs authorized use, the radiation safety officer's responsibilities, dosimetry, and safety procedures for F-18 and other PET radionuclides; 10 CFR Part 20 sets the occupational and public dose limits that frame the program.⁸ X-ray output from the CT subsystem is separately regulated as a radiation-producing device under FDA and state authority.
SNMMI Procedure Standard for Sodium 18F-Fluoride PET/CT Bone Scans (current version 1.1) provides the professional framework for patient preparation, administered activity (~185–370 MBq in adults), uptake time, acquisition, and interpretation.¹ It is guidance, not regulation, but it is the reference of record for a defensible NaF protocol.
FDA. Sodium Fluoride F 18 Injection is an FDA-approved radiopharmaceutical with prescribing information covering indications, dosing, and handling; PET drug production is governed by the FDA's current good manufacturing practice framework for PET drugs.⁴
Dosimetry basis. Patient dose estimates should use current ICRP radiopharmaceutical dose coefficients (ICRP Publication 128 and predecessors), which give an F-18 fluoride effective dose coefficient of approximately 0.024 mSv/MBq with the urinary bladder wall as the critical organ.²⁴

Jurisdiction note for the states DRPS serves: Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use of byproduct material under their own radiation-control programs, while Washington DC and Delaware are regulated directly by the NRC. Confirm which authority issues your license and which reporting and dose requirements apply before relying on any protocol assumption.

Frequently Asked Questions (FAQs)

What is F-18 sodium fluoride (NaF) PET/CT?

F-18 sodium fluoride PET/CT is a bone imaging study that uses the positron-emitting tracer F-18 fluoride, which is taken up at sites of active bone turnover and incorporated into the bone mineral matrix. Combined with CT for anatomic localization and attenuation correction, it produces high-resolution, quantitative images of osteoblastic activity for indications such as detecting bone metastases.

How is NaF PET/CT different from a Tc-99m MDP bone scan?

Both image bone turnover, but NaF PET/CT offers higher spatial resolution, higher target-to-background ratio, a much shorter uptake time (typically 30–90 minutes versus 2–4 hours), tomographic imaging with integrated CT, and quantitative SUV. F-18 NaF generally has higher sensitivity for skeletal lesions, at the cost of PET/CT scanner time and higher equipment requirements.

What activity of F-18 NaF is administered and what is the uptake time?

The SNMMI procedure standard recommends an adult administered activity of roughly 185–370 MBq (5–10 mCi), with imaging performed after an uptake period of about 30–90 minutes (commonly 45–60 minutes). Actual activity and timing depend on the scanner, protocol, and patient size.

What is the radiation dose from an F-18 NaF PET/CT study?

Using the ICRP effective dose coefficient of about 0.024 mSv/MBq for F-18 fluoride, a 185–370 MBq administration delivers roughly 4.4–8.9 mSv from the tracer alone. The CT component adds several additional mSv depending on technique, so a combined whole-body NaF PET/CT is commonly on the order of 8–14 mSv. The urinary bladder wall is the critical organ, so hydration and frequent voiding reduce dose.

Why does bone attenuation matter for NaF quantification?

Bone is highly attenuating, and accurate attenuation correction is essential for correct SUV. On PET/CT the CT provides an accurate attenuation map, but on PET/MR, standard MR-based attenuation correction that ignores bone can underestimate SUV in the spine and pelvis by roughly 8%. This is a key reason NaF quantification is more straightforward on PET/CT than on PET/MR.

How does time-of-flight (TOF) affect NaF SUV?

TOF reconstruction improves the statistical quality of PET data and modestly raises measured SUV in small osseous structures relative to non-TOF reconstruction. The effect is real but generally small; because it is reconstruction-dependent, TOF versus non-TOF differences should be held constant when tracking SUV across serial studies or multicenter trials.

What QC does a NaF PET/CT program need?

NaF PET/CT relies on the same quantitative PET QC as any SUV-based program: dose-calibrator accuracy and constancy, scanner–dose-calibrator–clock cross-calibration, daily normalization and calibration checks, NEMA NU 2 performance characterization, and CT QC. Consistent reconstruction settings and accurate injected-activity and time records are essential for reliable SUV.

Key Takeaways

NaF is a bone-seeking PET tracer that chemisorbs into hydroxyapatite at sites of active turnover, imaging osteoblastic activity with high resolution and target-to-background.¹⁵
It outperforms Tc-99m MDP on resolution, quantitation, and uptake time, with generally higher skeletal sensitivity — at the cost of PET/CT resources.¹⁵
Quantification is SUV-based and depends on accurate decay correction, cross-calibration, and consistent reconstruction; TOF nudges small-lesion SUV upward.⁶⁷
Attenuation correction is the NaF-specific pitfall: CT-based AC is robust, but bone-ignoring MR AC underestimates spinal/pelvic SUV by ~8%.⁵⁶
Dosimetry: ~0.024 mSv/MBq effective dose coefficient, bladder wall critical; a full study is commonly ~8–14 mSv including CT.²⁴
QC and standards: follow the SNMMI NaF procedure standard, characterize the scanner with NEMA NU 2, and run the study under the 10 CFR Part 35 medical-use framework.¹⁷⁸

Conclusion

F-18 NaF PET/CT turns the familiar physiology of the bone scan into a high-resolution, quantitative PET study. That power comes with quantitative obligations: the SUV numbers that make NaF valuable for detection and response assessment are only trustworthy when the dose-calibrator, cross-calibration, timing, reconstruction, and attenuation-correction chain is disciplined and documented. Handle the tracer physics, dosimetry, and QC deliberately — and understand where bone attenuation can bite on PET/MR — and NaF PET/CT is one of the most capable skeletal imaging tools available.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine and PET/CT facilities running NaF and other quantitative PET programs with PET/CT and nuclear medicine physics services: dose-calibrator and scanner cross-calibration, NEMA NU 2 performance testing, SUV-integrity reviews, attenuation-correction evaluation, protocol and dosimetry review against SNMMI and ICRP references, and accreditation support and radioactive material license support.

DRPS serves facilities across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware. See our service locations or contact us to discuss a NaF PET/CT program.

Related Resources

References

Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51(11):1813-1820. doi:10.2967/jnumed.110.082263. doi.org
Society of Nuclear Medicine and Molecular Imaging. SNMMI Procedure Standard for Sodium 18F-Fluoride PET/CT Bone Scans, Version 1.1. Reston, VA: SNMMI. snmmi.org
Harmon SA, Perk T, Lin C, et al. Quantitative assessment of early [18F]sodium fluoride PET/CT response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol. 2017;35(24):2829-2837. doi:10.1200/JCO.2017.72.2348. doi.org
Marafi F, Esmail A, Rasheed R, Alkandari F, Usmani S. Novel weight-based dose threshold for 18F-NaF PET-CT imaging using advanced PET-CT systems: a potential tool for reducing radiation burden. Nucl Med Commun. 2017;38(9):764-770. doi:10.1097/MNM.0000000000000706. doi.org
Schramm G, Maus J, Hofheinz F, et al. Correction of quantification errors in pelvic and spinal lesions caused by ignoring higher photon attenuation of bone in [18F]NaF PET/MR. Med Phys. 2015;42(11):6468-6476. doi:10.1118/1.4932367. doi.org
Karakatsanis NA, Abgral R, Trivieri MG, et al. Hybrid PET- and MR-driven attenuation correction for enhanced 18F-NaF and 18F-FDG quantification in cardiovascular PET/MR imaging. J Nucl Cardiol. 2020;27(4):1126-1141. doi:10.1007/s12350-019-01928-0. doi.org
Oldan JD, Turkington TG, Choudhury K, Chin BB. Quantitative differences in [18F]NaF PET/CT: TOF versus non-TOF measurements. Am J Nucl Med Mol Imaging. 2015;5(5):504-514. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Ann ICRP. 2015;44(2S). icrp.org
National Electrical Manufacturers Association. NEMA Standards Publication NU 2: Performance Measurements of Positron Emission Tomographs (PET). Rosslyn, VA: NEMA. nema.org